Major Funds Retreat from UnitedHealth Shares Ahead of Dividend Payout

Unitedhealth US91324P1021

A notable shift is occurring among UnitedHealth Group's institutional shareholders as the healthcare giant approaches a key December date. Despite the company's solid operational performance, several large-scale investors have been scaling back their holdings, casting a shadow over the stock's recent performance.

Leading the sell-off is the California Public Employees' Retirement System (CalPERS). Regulatory filings with the U.S. Securities and Exchange Commission reveal the pension fund disposed of approximately 373,000 UnitedHealth shares. This transaction represents a nearly 15% reduction in its position. While CalPERS retains a substantial holding of about 2.16 million shares valued at $674.6 million, the partial exit by such a significant, long-term investor is widely interpreted as a cautionary signal for the market.

CalPERS is not alone in its retreat. Epoch Investment Partners, for instance, sold close to 500,000 shares during the second quarter—an 82% decrease in its stake. These moves coincide with a challenging period for the equity, which has declined more than 30% in value since the start of the year.

Dividend Date Offers a Silver Lining

For income-focused investors, however, a near-term incentive remains. UnitedHealth is scheduled to distribute a quarterly dividend of $2.21 per share on December 16. To qualify for this payment, shareholders must be on record by the close of business on December 8.

Annualized, the dividend totals $8.84 per share. At the current share price near $331, this translates to a yield of approximately 2.7%. This income stream offers some consolation to holders navigating the stock's pronounced downturn.

Strategic Refocus Underway

Concurrently, UnitedHealth is streamlining its international portfolio. The company has agreed to sell its South American unit, Banmedica, to a Brazilian private-equity investor for roughly $1 billion. The strategic intent behind this divestiture is a sharper focus on its core U.S. operations and the expanding Optum services segment.

Fundamentally, the business continues to show strength. For the third quarter of 2025, UnitedHealth grew revenue by over 12% to $113.2 billion. Management has reaffirmed its full-year adjusted earnings per share guidance of at least $16.25.

Divergent Views on Market Direction

Analyst perspectives present a mixed picture, creating a contrast with the institutional selling activity. Some observers remain wary due to the steep price decline, while others spy a potential buying opportunity. Wolfe Research recently raised its price target from $330 to $375, citing anticipated margin improvements and growth within the Optum segment.

The coming week is poised to be pivotal. The December 8 dividend record date may provide short-term technical support for the share price. In the medium term, however, the direction will likely be influenced by the continued selling pressure from major funds. With a price-to-earnings ratio around 17 and an attractive dividend yield, the valuation appears moderate. The central question for markets is whether these factors will be sufficient to restore broader investor confidence.